Our current portfolio includes novel clinical-stage assets, as well as multiple research stage molecules. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Olinciguat is a clinical-stage, oral, once-daily, vascular sGC stimulator that we intend to out-license for cardiovascular diseases. Olinciguat demonstrates broad pharmacology including effects on vascular function, inflammation, and fibrosis in multiple preclinical models. Clinical studies have demonstrated a well-tolerated dose range, dose-proportional pharmacokinetics, and target engagement.
Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease. In preclinical studies, praliciguat demonstrated extensive distribution to key target tissues including adipose tissue, kidney, heart, and liver; the extensive, extra-vascular distribution of praliciguat has been confirmed in clinical studies.
Zagociguat and CY3018 are CNS-penetrant sGC stimulators that were developed at Cyclerion and were sold to Tisento Therapeutics, Inc., a company in which Cyclerion holds a 10% equity stake. Zagociguat is a clinical-stage CNS-penetrant sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a CNS-targeted sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders.
Cyclerion is actively evaluating other activities aimed at enhancing shareholder value, which may potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.